Aging Cell: 肿瘤抑制因子miR-34c作为AD治疗新靶点

2022-08-31 brainnew神内神外 brainnews白色世界发表于上海

解密阿尔茨海默病和肿瘤发生负相关的分子机理

流行病学研究表明，阿尔茨海默病（AD）与癌症之间存在负相关性，河北医科大学徐顺江教授团队因此关注到肿瘤抑制因子miR-34c的上游信号通路和下游分子机制在AD病理中起着关键作用，在Aging Cell上发表题为Increased miR‐34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS‐JNK‐p53 pathway in Alzheimer’s Disease的文章，讲述通过ROS-JNK-p53途径和miR-34c/SYT1途径可靶向SYT1，增加miR-34c介导的突触和记忆缺陷，被认为是AD患者新的治疗靶点。

1miR-34c受ROC-JNK-p53调控，且与AD病理相关

本研究首先在体内(SAMP8小鼠模型-衰老加速模型)及体外(H2O2刺激的氧化应激神经元和Aβ42刺激的AD细胞模型)确定miR-34c的表达水平增加。结果发现ROS产生、JNK激活、p53积累参与SAMP8小鼠海马神经元损伤，这表明ROS-JNK-p53通路参与AD病理过程。本研究进一步验证氧化应激诱导的miR-34c的增加是由ROS-JNK-p53途径介导。

2miR-34c靶向调节SYT1

生物信息学分析预测miR-34c的靶基因，并进行验证。结果显示miR-34c直接结合SYT1 mRNA序列的3'-UTR，同时表明miR-34c在神经元中SYT1(突触前神经末梢释放神经递质中起关键作用)表达的转录后调节中起功能性作用，并在小鼠模型中得到验证。以上结果证实了ROS-JNK-p53途径和miR-34c/SYT1途径在AD中的分子机制。接着通过SAMP8小鼠模型表明SM34c抑制miR-34c可减轻Aβ诱导的突触衰竭，改善认知缺陷。

3轻度认知障碍(aMCI)患者血清miR-34c水平升高

aMCI是正常衰老和痴呆之间的过渡阶段，代表AD的早期阶段。临床实验证实aMCI患者miR-34c血清水平升高，且与MMSE评分呈正相关。进一步使用ROC曲线评估miR-34c对aMCI诊断价值，结果显示循环miR-34c可能是诊断的预测生物标志物。

图. aMCI患者血清miR-34c表达水平升高

AD是与衰老相关的疾病，关键病理学标志之一为Aβ的异常积累，会导致突触丧失、神经元死亡和记忆缺陷，而海马突触可塑性的下降是AD的早期事件。癌症是老年人中普遍存在的另一种疾病，其特征是细胞增殖的不受控。一些流行病学报告AD与癌症之间存在负相关。本文从细胞途径和分子机制的角度探讨肿瘤抑制因子在AD中的作用，将有助于开辟针对这两种疾病的预防和治疗新领域。

编译作者：小飞侠 (Brainnews创作团队)

校审：Victoria, Simon (Brainnews编辑部)

参考文献：

Shi Z, Zhang K, Zhou H, et al. Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer's Disease. Aging Cell. 2020;19(3):e13125. doi:10.1111/acel.13125

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2022-08-03 smallant2002

#miR#

45 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2022-05-15 zhaozhouchifen

#Cell#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2022-10-16 lxg962

#肿瘤抑制因子#

39 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2022-08-25 tsing_hit

#肿瘤抑制#

41 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2022-01-30 维他命

#CEL#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2021-11-10 lsndxfj

#新靶点#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2021-11-10 12498f1em11(暂无昵称)

#治疗新靶点#

45 0
[GetPortalCommentsPageByObjectIdResponse(id=1930871, encodeId=184e19308e1cb, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Aug 03 21:04:21 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872522, encodeId=710018e2522a1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun May 15 18:04:21 CST 2022, time=2022-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718808, encodeId=502a1e1880859, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Sun Oct 16 03:04:21 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809172, encodeId=07ad18091e256, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Thu Aug 25 00:04:21 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962852, encodeId=045319628526a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jan 30 12:04:21 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288355, encodeId=1650128835594, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517407, encodeId=e8f3151e4072a, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532103, encodeId=dfac153210318, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Wed Nov 10 01:04:21 CST 2021, time=2021-11-10, status=1, ipAttribution=)]
2021-11-10 shalley70

#抑制因子#

34 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

神经科

Aging Cell: 肿瘤抑制因子miR-34c作为AD治疗新靶点

相关资讯

科室

工具

服务